このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Anavex Life Sciences 将来の成長

Future 基準チェック /06

Anavex Life Sciencesは、19.2%と99.3%でそれぞれ年率19.2%で利益と収益が成長すると予測される一方、EPSはgrowで22.4%年率。

主要情報

19.2%

収益成長率

22.4%

EPS成長率

Biotechs 収益成長	24.2%
収益成長率	99.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Jun 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Apr 01

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Sep 19

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

May 10

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Jan 16

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Oct 01

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Sep 19

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Sep 07

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Aug 09

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Jun 17

Anavex: Increasing Shareholder Value Against All Odds

May 31

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

Mar 23

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Mar 03

Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease

Feb 09

Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity

Feb 02

Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers

Jun 21

Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease

Jun 14

Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment

Jun 08

Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease

Apr 28

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Apr 16

Anavex shares up 65% in morning trading continuing hot streak

Feb 04

Anavex Life Sciences Corp.: 2021 Clinical Milestones Support Bullish Momentum

Jan 05

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Jan 01

Anavex Life Sciences EPS beats by $0.06

Dec 28

Anavex's blarcamesine successful in mid-stage rett syndrome study

Dec 15

業績と収益の成長予測

NasdaqGS:AVXL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2026	3	-35	N/A	N/A	1
9/30/2025	N/A	-57	N/A	N/A	2
9/30/2024	N/A	-44	N/A	N/A	2
3/31/2024	N/A	-41	-32	-32	N/A
12/31/2023	N/A	-43	-29	-29	N/A
9/30/2023	N/A	-48	-28	-28	N/A
6/30/2023	N/A	-52	-26	-26	N/A
3/31/2023	N/A	-53	-25	-25	N/A
12/31/2022	N/A	-50	-27	-27	N/A
9/30/2022	N/A	-48	-24	-24	N/A
6/30/2022	N/A	-45	-28	-28	N/A
3/31/2022	N/A	-43	-28	-28	N/A
12/31/2021	N/A	-41	-26	-26	N/A
9/30/2021	N/A	-38	-30	-30	N/A
6/30/2021	N/A	-32	-29	-29	N/A
3/31/2021	N/A	-28	-25	-25	N/A
12/31/2020	N/A	-28	-23	-23	N/A
9/30/2020	N/A	-26	-21	-21	N/A
6/30/2020	N/A	-26	-18	-18	N/A
3/31/2020	N/A	-26	-21	-21	N/A
12/31/2019	N/A	-26	-20	-20	N/A
9/30/2019	N/A	-26	-19	-19	N/A
6/30/2019	N/A	-26	-20	-20	N/A
3/31/2019	N/A	-23	-15	-15	N/A
12/31/2018	N/A	-20	-13	-13	N/A
9/30/2018	N/A	-17	-13	-13	N/A
6/30/2018	N/A	-17	-11	-11	N/A
3/31/2018	N/A	-18	-12	-12	N/A
12/31/2017	N/A	-14	N/A	-9	N/A
9/30/2017	N/A	-13	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-9	N/A
3/31/2017	N/A	-13	N/A	-8	N/A
12/31/2016	N/A	-14	N/A	-9	N/A
9/30/2016	N/A	-15	N/A	-9	N/A
6/30/2016	N/A	-14	N/A	-9	N/A
3/31/2016	N/A	-16	N/A	-8	N/A
12/31/2015	N/A	-15	N/A	-7	N/A
9/30/2015	N/A	-12	N/A	-4	N/A
6/30/2015	N/A	-15	N/A	-4	N/A
3/31/2015	N/A	-12	N/A	-3	N/A
12/31/2014	N/A	-11	N/A	-3	N/A
9/30/2014	N/A	-10	N/A	-3	N/A
6/30/2014	N/A	-5	N/A	-2	N/A
3/31/2014	N/A	-4	N/A	-1	N/A
12/31/2013	N/A	-3	N/A	-1	N/A
9/30/2013	N/A	-4	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AVXL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AVXL今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: AVXL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AVXL来年は収益がないと予測されています。

高い収益成長: AVXL来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AVXLの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Anavex Life Sciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 26% to US$40.00

Forecast to breakeven in 2025

Price target increased by 19% to US$47.00

Price target increased by 30% to US$41.67

Price target decreased to US$33.25

Forecast to breakeven in 2025

Recent updates

Insufficient new directors

Anavex Life Sciences Corp Announces Management Appointments

Anavex Life Sciences Corp., Annual General Meeting, Jun 18, 2024

Anavex Life Sciences Corp. to Report Q2, 2024 Results on May 09, 2024

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

President notifies of intention to sell stock

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®?3-71 in Schizophrenia

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Anavex Life Sciences Corp. to Report Q1, 2024 Results on Feb 07, 2024

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia

Price target decreased by 26% to US$40.00

Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome

Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

New major risk - Revenue and earnings growth

Anavex Life Sciences Corp. to Report Fiscal Year 2023 Results on Nov 27, 2023

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency

Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs

Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease

New major risk - Revenue and earnings growth

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Anavex Life Sciences Corp. Announces Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Anavex Life Sciences Reports Publication of ANAVEX®?3-71 in Clinical Journal Confirming ANAVEX®? 3-71 Clinical Cardiovascular Safety

Anavex Life Sciences Corp. to Report Q3, 2023 Results on Aug 08, 2023

Chairman notifies of intention to sell stock

Anavex Life Sciences Corp. Announces Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX(R)2-73 (blarcamesine) for Rett Syndrome

Anavex Life Sciences Corp.'s ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Anavex Life Sciences Corp. Announces Completion of Anavex((R))2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial

Forecast to breakeven in 2025

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Price target increased by 19% to US$47.00

Anavex Life Sciences Corp. Announces Exceeding of Enrollment Target for the ANAVEX(R)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. to Report Q1, 2023 Results on Feb 07, 2023

Price target increased by 30% to US$41.67

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Anavex Life Sciences Corp. Announces the Appointment of Timo Grimmer, Md, to Its Scientific Advisory Board

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. to Report Q4, 2022 Results on Nov 28, 2022

Price target decreased to US$33.25

Insufficient new directors

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2B/3 Data of Oral Anavex®2-73 (Blarcamesine) for Early Alzheimer’s Disease At the Upcoming Clinical Trials on Alzheimer’S Disease (Ctad) Congress 2022

Forecast to breakeven in 2025

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Anavex Life Sciences Corp. Reports New Publication in Medical Journal Highlighting the Relevance of Sigmar1 Activation to Compensate for Early Alzheimer's Disease

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Anavex Life Sciences Corp. to Report Q3, 2022 Results on Aug 09, 2022

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex: Increasing Shareholder Value Against All Odds

Independent Director exercised options and sold US$407k worth of stock

Anavex Life Sciences Corp. to Report Q2, 2022 Results on May 10, 2022

Price target decreased to US$31.00

Insufficient new directors

Anavex Life Sciences Corp., Annual General Meeting, May 24, 2022

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome

Anavex Life Sciences Corp. to Report Q1, 2022 Results on Feb 09, 2022

Price target decreased to US$30.94

Anavex Life Sciences Corp. Reports Positive Top-Line Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled AVATAR trial of ANAVEX®2-73

Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity

Anavex: 2022 Has Major, Pivotal Catalysts

Anavex Life Sciences Corp. Reports Positive Results from Phase 1 Clinical Trial of ANAVEX3-71

Forecast to breakeven in 2024

No longer forecast to breakeven

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?